抗中心粒细胞胞浆抗体检测在儿科疾病中的应用
收稿日期: 2022-07-13
网络出版日期: 2022-10-12
The application of anti-neutrophil cytoplasmic antibodies tests in pediatric diseases
Received date: 2022-07-13
Online published: 2022-10-12
抗中性粒细胞胞浆抗体(ANCA)是一类以中性粒细胞和单核细胞胞浆成分为靶抗原的自身抗体。ANCA包括胞浆型(c-ANCA)、核周型(p-ANCA)和非典型(a-ANCA)。其中c-ANCA、p-ANCA的靶抗原分别是蛋白酶3和髓过氧化物酶。目前ANCA检测技术主要包括间接免疫荧光法、酶联免疫吸附法、化学发光法和荧光酶免疫法等。ANCA相关性血管炎是一种主要累及中小血管的坏死性血管炎,寡或无免疫复合物沉积,儿童发病率低,但起病急,进展快,临床表现多样化,停药后疾病易复发。ANCA已成为诊断儿童肉芽肿性血管炎、显微镜下血管炎和嗜酸性粒细胞肉芽肿性血管炎等系统性血管炎的重要标记物。ANCA检测有助于ANCA相关性血管炎的早期诊治,从而改善疾病预后。
关键词： 抗中心粒细胞胞浆抗体; 蛋白酶3; 髓过氧化物酶; ANCA相关性血管炎
康郁林 . 抗中心粒细胞胞浆抗体检测在儿科疾病中的应用[J]. 临床儿科杂志, 2022 , 40(10) : 733 -738 . DOI: 10.12372/jcp.2022.22e0962
Anti-neutrophil cytoplasmic antibodies (ANCA) are a class of autoantibodies that target the cytoplasmic components of neutrophils and monocytes. ANCA includes cytoplasmic ANCA (c-ANCA), perinuclear ANCA (p-ANCA) and atypical ANCA (a-ANCA). The target antigens of c-ANCA and p-ANCA are proteinase 3 and myeloperoxidase, respectively. At present, the ANCA detection assay mainly includes indirect immunofluorescence, enzyme-linked immunosorbent assay, chemiluminescent immunoassays and fluorescent-enzyme immunoassays. ANCA associated vasculitis (AAV) is a necrotizing vasculitis mainly involving small and medium sized arteries with pauci-immune deposits. The incidence of AAV is low in children, but the onset of the disease is urgent, the progression is rapid, the clinical manifestations are diverse, and the disease is easy to relapse after drug withdrawal. ANCA has become an important marker for the diagnosis of granulomatous vasculitis, microscopic vasculitis and eosinophilic granulomatous vasculitis. ANCA detection is helpful for the early diagnosis and treatment of AAV, thus improving the prognosis of the disease.
| [1] | Suwanchote S, Rachayon M, Rodsaward P, et al. Anti-neutrophil cytoplasmic antibodies and their clinical significance[J]. Clin Rheumatol, 2018, 37(4): 875-884. |
| [2] | Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis)[J]. Arthritis Rheum, 1990, 33(8): 1094-1100. |
| [3] | Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides[J]. Arthritis Rheum, 2013, 65(1): 1-11. |
| [4] | Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis[J]. Arthritis Rheumatol, 2022, 74(3): 393-399. |
| [5] | Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis[J]. Ann Rheum Dis, 2022, 81(3): 309-314. |
| [6] | Suppiah R, Robson JC, Grayson PC, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis[J]. Arthritis Rheumatol, 2022, 74(3): 400-406. |
| [7] | Ramponi G, Folci M, De Santis M, et al. The biology, pathogenetic role, clinical implications, and open issues of serum anti-neutrophil cytoplasmic antibodies[J]. Autoimmun Rev, 2021, 20(3): 102759. |
| [8] | Bannard O, Cyster JG. Germinal centers: programmed for affinity maturation and antibody diversification[J]. Curr Opin Immunol, 2017, 45: 21-30. |
| [9] | Kemna MJ, Schlumberger W, van Paassen P, et al. The avidity of PR3-ANCA in patients with granulomatosis with polyangiitis during follow-up[J]. Clin Exp Immunol, 2016, 185(2): 141-147. |
| [10] | Land J, Rutgers A, Kallenberg CG. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody[J]. Nephrol Dial Transplant, 2014, 29(4): 739-745. |
| [11] | Alberici F, Martorana D, Bonatti F, et al. Genetics of ANCA-associated vasculitides: HLA and beyond[J]. Clin Exp Rheumatol, 2014, 32(3 Suppl 82): S90-S97. |
| [12] | Pendergraft WF 3rd, Preston GA, Shah RR, et al. Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3[J]. Nat Med, 2004, 10(1): 72-79. |
| [13] | Jariwala MP, Laxer RM. Primary vasculitis in childhood: GPA and MPA in childhood[J]. Front Pediatr, 2018, 6: 226. |
| [14] | Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions[J]. Arthritis Care Res, 2000, 13(6): 424-434. |
| [15] | Guchelaar NAD, Waling MM, Adhin AA, et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis[J]. Autoimmun Rev, 2021, 20(1): 102716. |
| [16] | 中国免疫学会临床免疫学分会. 抗中性粒细胞胞浆抗体检测方法在诊断肉芽肿性血管炎和显微镜下多血管炎中应用的专家共识[J]. 中华医学杂志, 2019, 99(38): 2971-2975. |
| [17] | Robson JC, Grayson PC, Ponte C, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis[J]. Ann Rheum Dis, 2022, 81(3): 315-320. |
| [18] | Iudici M, Pagnoux C, Quartier P, et al. Childhood- versus adult-onset ANCA-associated vasculitides: A nested, matched case-control study from the French Vasculitis Study Group Registry[J]. Autoimmun Rev, 2018, 17(2): 108-114. |
| [19] | 陈丽植, 蒋小云. 儿童抗中性粒细胞胞质抗体相关性血管炎的诊治进展[J]. 中华实用儿科临床杂志, 2020, 35(17): 1313-1319. |
| [20] | Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides[J]. Ann Rheum Dis, 2006, 65(7): 936-941. |
| [21] | Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria[J]. Ann Rheum Dis, 2010, 69(5): 798-806. |
| [22] | Lakhani DA, Balar AB, Adelanwa A, et al. Granulomatosis with polyangiitis: a case report and brief review of literature[J]. Radiol Case Rep, 2021, 16(11): 3445-3450. |
| [23] | Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis[J]. Arthritis Rheumatol, 2022, 74(3): 386-392. |
| [24] | Sokolowska BM, Szczeklik WK, Wludarczyk AA, et al. ANCA-positive and ANCA-negative phenotypes of eosinophilic granulomatosis with polyangiitis (EGPA): outcome and long-term follow-up of 50 patients from a single Polish center[J]. Clin Exp Rheumatol, 2014, 32(3 Suppl 82): S41-S47. |
| [25] | Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort[J]. Arthritis Rheum, 2013, 65(1): 270-281. |
| [26] | 孙良忠, 王海燕. 儿童显微镜下多血管炎诊治进展[J]. 中华实用儿科临床杂志, 2017, 32(5): 333-337. |
| [27] | Shah S, Havill J, Rahman MH, et al. A historical study of American patients with anti-neutrophil cytoplasmic antibody negative pauci-immune glomerulonephritis[J]. Clin Rheumatol, 2016, 35(4): 953-960. |
| [28] | Alawneh D, Edrees A. Hydralazine-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a case report and literature review[J]. Cureus, 2022, 14(4): e24132. |
| [29] | Tomkins M, Tudor RM, Smith D, et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis and agranulocytosis in a patient with Graves' disease[J]. Endocrinol Diabetes Metab Case Rep, 2020: 19-0135. |
| [30] | Jin Q, Kant S, Alhariri J, et al. Levamisole adulterated cocaine associated ANCA vasculitis: review of literature and update on pathogenesis[J]. J Community Hosp Intern Med Perspect, 2018, 8(6): 339-344. |
| [31] | Land J, Abdulahad WH, Arends S, et al. Prospective monitoring of in vitro produced PR3-ANCA does not improve relapse prediction in granulomatosis with polyangiitis[J]. PLoS One, 2017, 12(8): e0182549. |
| [32] | Mahadeva R, Dunn AC, Westerbeek RC, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) against bactericidal/permeability-increasing protein (BPI) and cystic fibrosis lung disease[J]. Clin Exp Immunol, 1999, 117(3): 561-567. |
| [33] | Wunsch E, Norman GL, Milkiewicz M, et al. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis[J]. Aliment Pharmacol Ther, 2021, 53(2): 302-313. |
/
| 〈 |
|
〉 |
沪公网安备 31011002000392号
